Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$9.15
-0.8%
$8.99
$7.11
$11.90
$1.23B1.631.33 million shs733,009 shs
CareDx, Inc. stock logo
CDNA
CareDx
$12.75
+7.1%
$18.23
$10.96
$34.84
$709.92M2.191.03 million shs4.55 million shs
Enhabit, Inc. stock logo
EHAB
Enhabit
$6.70
-0.8%
$9.34
$6.50
$10.91
$339.04M1.72489,408 shs855,941 shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$16.79
+1.6%
$14.80
$9.90
$27.20
$1.37B0.391.14 million shs661,274 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
0.00%0.00%+9.89%+25.78%-13.35%
CareDx, Inc. stock logo
CDNA
CareDx
0.00%-40.83%-37.45%-29.69%-34.16%
Enhabit, Inc. stock logo
EHAB
Enhabit
0.00%-3.69%-26.63%-6.22%-28.45%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.00%-3.05%+12.23%+25.82%+14.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
3.7181 of 5 stars
3.51.00.00.03.31.73.1
CareDx, Inc. stock logo
CDNA
CareDx
4.1607 of 5 stars
3.31.00.04.22.90.81.9
Enhabit, Inc. stock logo
EHAB
Enhabit
3.4627 of 5 stars
3.34.00.00.02.90.02.5
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
3.2473 of 5 stars
4.55.00.00.02.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
3.00
Buy$13.4045.57% Upside
CareDx, Inc. stock logo
CDNA
CareDx
2.67
Moderate Buy$29.33129.26% Upside
Enhabit, Inc. stock logo
EHAB
Enhabit
2.50
Moderate Buy$8.7530.31% Upside
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.90
Moderate Buy$37.56120.98% Upside

Current Analyst Ratings Breakdown

Latest EHAB, VRDN, AHCO, and CDNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
CareDx, Inc. stock logo
CDNA
CareDx
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $26.00
5/20/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/12/2025
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $13.00
5/8/2025
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$14.00 ➝ $13.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$31.00 ➝ $27.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$46.00 ➝ $45.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $36.00
5/5/2025
CareDx, Inc. stock logo
CDNA
CareDx
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$40.00 ➝ $40.00
5/5/2025
CareDx, Inc. stock logo
CDNA
CareDx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00
4/23/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$34.00 ➝ $34.00
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$3.26B0.38$3.79 per share2.43$11.72 per share0.79
CareDx, Inc. stock logo
CDNA
CareDx
$333.79M2.13$1.46 per share8.76$7.06 per share1.81
Enhabit, Inc. stock logo
EHAB
Enhabit
$1.03B0.33$4.07 per share1.65$10.92 per share0.61
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$300K4,622.07N/AN/A$6.09 per share2.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$90.42M$0.5716.189.491.072.63%6.96%2.40%8/5/2025 (Estimated)
CareDx, Inc. stock logo
CDNA
CareDx
$52.55M$1.1511.19N/AN/A19.79%21.16%14.25%7/30/2025 (Estimated)
Enhabit, Inc. stock logo
EHAB
Enhabit
-$156.20M-$2.77N/A23.16N/A-13.43%2.02%0.94%8/6/2025 (Estimated)
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$269.95M-$3.85N/AN/AN/A-102,092.39%-70.61%-44.67%8/14/2025 (Estimated)

Latest EHAB, VRDN, AHCO, and CDNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$1.01N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.10N/AN/AN/A$263.39 millionN/A
8/5/2025Q2 2025
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$0.15N/AN/AN/A$804.97 millionN/A
7/30/2025Q2 2025
CareDx, Inc. stock logo
CDNA
CareDx
$0.12N/AN/AN/A$90.72 millionN/A
5/7/2025Q1 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.07$0.10+$0.03$0.35$266.11 million$259.90 million
5/6/2025Q1 2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$0.95-$0.87+$0.08-$0.87$0.16 million$0.07 million
4/30/2025Q1 2025
CareDx, Inc. stock logo
CDNA
CareDx
$0.06$0.09+$0.03-$0.19$84.56 million$84.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
N/AN/AN/AN/AN/A
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
N/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
1.25
1.29
1.07
CareDx, Inc. stock logo
CDNA
CareDx
N/A
4.11
3.84
Enhabit, Inc. stock logo
EHAB
Enhabit
0.82
1.49
1.49
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.05
19.49
19.49

Institutional Ownership

CompanyInstitutional Ownership
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
82.67%
CareDx, Inc. stock logo
CDNA
CareDx
N/A
Enhabit, Inc. stock logo
EHAB
Enhabit
N/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
1.55%
CareDx, Inc. stock logo
CDNA
CareDx
4.40%
Enhabit, Inc. stock logo
EHAB
Enhabit
3.40%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
10,500134.95 million132.86 millionOptionable
CareDx, Inc. stock logo
CDNA
CareDx
74055.68 million53.23 millionOptionable
Enhabit, Inc. stock logo
EHAB
Enhabit
10,70050.64 million48.92 millionOptionable
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
5081.59 million81.06 millionOptionable

Recent News About These Companies

Viridian Therapeutics: The Song Remains The Same

New MarketBeat Followers Over Time

Media Sentiment Over Time

AdaptHealth stock logo

AdaptHealth NASDAQ:AHCO

$9.15 -0.07 (-0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$9.29 +0.14 (+1.53%)
As of 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.

CareDx stock logo

CareDx NASDAQ:CDNA

$12.75 +0.84 (+7.05%)
Closing price 04:00 PM Eastern
Extended Trading
$12.75 +0.00 (+0.03%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Enhabit stock logo

Enhabit NYSE:EHAB

$6.70 -0.06 (-0.81%)
Closing price 03:58 PM Eastern
Extended Trading
$6.71 +0.01 (+0.22%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.

Viridian Therapeutics stock logo

Viridian Therapeutics NASDAQ:VRDN

$16.79 +0.27 (+1.63%)
Closing price 04:00 PM Eastern
Extended Trading
$16.78 0.00 (-0.03%)
As of 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.